ID
UTHR icon

Integral Derivatives’s United Therapeutics UTHR Stock Holding History

Integral Derivatives’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-8,700
Closed -$1.51M – 1262
2015
Q2 		$1.51M Buy
+8,700
New +$1.57M 0.04% 406
2014
Q1 		– Sell
-2,200
Closed -$249K – 1594
2013
Q4 		$249K Buy
+2,200
New +$198K ﹤0.01% 1279

Other funds holding UTHR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return

Integral Derivatives's UTHR Position: Q3 2017 in Review

Integral Derivatives sold out of United Therapeutics (UTHR) in Q3 2017, closing a stake of 2,686 shares — an estimated $348K sold.

Integral Derivatives first reported a position in UTHR in Q1 2017 and held it in 2 quarters. The position peaked at $375K in Q1 2017. 373 funds tracked by Wall St. Rank hold UTHR as of Q3 2017.

  • Integral Derivatives reported no remaining United Therapeutics position as of Q3 2017 after selling out during the quarter.
  • Integral Derivatives sold 2,686 United Therapeutics shares in Q3 2017, an estimated $348K.
  • Integral Derivatives first reported a position in United Therapeutics in Q1 2017 and held it in 2 quarters.
  • Integral Derivatives's United Therapeutics position peaked at $375K in Q1 2017.
  • 373 funds tracked by Wall St. Rank held United Therapeutics as of Q3 2017.

Based on Integral Derivatives's 13F filing for Q3 2017, filed 14 Nov 2017.